Literature DB >> 18476807

A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.

N Melda Yenerel1, Umut A Dinc, Ebru Gorgun.   

Abstract

PURPOSE: The aim of this study was to describe a case of sterile endophthalmitis after repeated intravitreal bevacizumab injections for the treatment of choroidal neovascularization secondary to angioid streaks.
METHODS: This study was done as a case report.
RESULTS: A 57-year-old man who received a third injection of intravitreal bevacizumab for the treatment of choroidal neovascularization owing to angioid streaks developed sterile endophthalmitis. The patient's condition improved after hourly topical steroid and antibiotic drops without a sequele.
CONCLUSIONS: The intravitreal injection of bevacizumab has the potential for the development of sterile endophthalmitis. The patients should be warned against this possible adverse reaction, especially after repeated injections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18476807     DOI: 10.1089/jop.2007.0126

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  9 in total

1.  A cluster of presumed, noninfectious endophthalmitis after intravitreal injection of bevacizumab: long-term follow-up.

Authors:  Federico Ricci; Antonio Calabrese; Cecilia De Felici; Filippo Missiroli; Marco Pileri; Federico Regine
Journal:  Digit J Ophthalmol       Date:  2016-05-16

2.  Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate.

Authors:  Shabari S Bhatt; Kimberly E Stepien; Komal Joshi
Journal:  Retina       Date:  2011-11       Impact factor: 4.256

3.  Treatment of myopic choroidal neovascularization with posterior sub-Tenon's bevacizumab injection (Avastin ®).

Authors:  I-Chia Liang; Yu-Ying Chang; Tong-Sheng Lee; Yi-Ru Lin; Kwan-Rong Liu
Journal:  Int Ophthalmol       Date:  2014-02-02       Impact factor: 2.031

4.  Case of endophthalmitis following intravitreal injections of bevacizumab.

Authors:  Shinya Komori; Akira Sawada; Tsutomu Oguni; Kiyofumi Mochizuki; Kiyofumi Ohkusu
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 5.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.

Authors:  Fengfu Li; Bernard Hurley; Yun Liu; Brian Leonard; May Griffith
Journal:  Open Ophthalmol J       Date:  2012-06-25

Review 7.  Sterile endophthalmitis after intravitreal injections.

Authors:  Joaquín Marticorena; Vito Romano; Francisco Gómez-Ulla
Journal:  Mediators Inflamm       Date:  2012-08-29       Impact factor: 4.711

8.  Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center".

Authors:  Inci Elif Erbahçeci; Kemal Ornek
Journal:  Retina       Date:  2012-06       Impact factor: 3.975

9.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.